Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 35INDUSTRY 20NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Prolymphocytic 1Leukemia, B-Cell 1

Interventions

Cytarabine 117Cyclophosphamide 88Etoposide 59Daunorubicin 58fludarabine phosphate 50Specimen Handling 49Methotrexate 49Filgrastim 48Vincristine 47Biopsy 47Rituximab 43Radiotherapy 34Dexamethasone 34Peripheral Blood Stem Cell Transplantation 32Doxorubicin 29Mitoxantrone 27Idarubicin 27Busulfan 27Azacitidine 27Prednisone 26Mercaptopurine 26Leucovorin 26fludarabine 25Decitabine 24Asparaginase 24venetoclax 23merphos 22Bortezomib 22Cyclosporine 20alvocidib 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × ofatumumab × Other hematologic neoplasm × Clear all
NCT01145209 2023-11-28

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
32 enrolled 16 charts
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01515176 2018-03-15

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
36 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡